Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Efbemalenograstim alfa LA by Evive Biotech for Epithelial Ovarian Cancer: Likelihood of Approval
Efbemalenograstim alfa LA is under clinical development by Evive Biotech and currently in Phase II for Epithelial Ovarian Cancer. According...
Efbemalenograstim alfa LA by Evive Biotech for Peritoneal Cancer: Likelihood of Approval
Efbemalenograstim alfa LA is under clinical development by Evive Biotech and currently in Phase II for Peritoneal Cancer. According to...
Efbemalenograstim alfa LA by Evive Biotech for Fallopian Tube Cancer: Likelihood of Approval
Efbemalenograstim alfa LA is under clinical development by Evive Biotech and currently in Phase II for Fallopian Tube Cancer. According...
Efbemalenograstim alfa LA by Evive Biotech for Cervical Cancer: Likelihood of Approval
Efbemalenograstim alfa LA is under clinical development by Evive Biotech and currently in Phase II for Cervical Cancer. According to...